



HAL
open science

Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants.

Marie-Ève Lebel, Karine Chartrand, Denis Leclerc, Alain Lamarre

► **To cite this version:**

Marie-Ève Lebel, Karine Chartrand, Denis Leclerc, Alain Lamarre. Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants.. *Vaccines*, 2016, 3 (3), pp.620-37. 10.3390/vaccines3030620 . pasteur-01352188

HAL Id: pasteur-01352188

<https://riip.hal.science/pasteur-01352188>

Submitted on 5 Aug 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Review

Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants

Marie-Ève Lebel ¹, Karine Chartrand ¹, Denis Leclerc ² and Alain Lamarre ^{1,*}

¹ Immunovirology laboratory, Institut national de la recherche scientifique, Institut Armand-Frappier, 531 Boulevard des Prairies, Laval, QC H1V 1B7, Canada;

E-Mails: Marie-Eve.Lebel@iaf.inrs.ca (M.-E.L.); Karine.Chartrand@iaf.inrs.ca (K.C.)

² Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Centre, Laval University, Quebec City, QC G1V 4G2, Canada;

E-Mail: Denis.Leclerc@crchudequebec.ulaval.ca

* Author to whom correspondence should be addressed; E-Mail: alain.lamarre@iaf.inrs.ca; Tel.: +1-450-687-5010 (ext. 4262); Fax: +1-450-686-5501.

Academic Editor: Darrell J. Irvine

Received: 15 June 2015 / Accepted: 29 July 2015 / Published: 5 August 2015

Abstract: Vaccines are considered one of the greatest medical achievements in the battle against infectious diseases. However, the intractability of various diseases such as hepatitis C, HIV/AIDS, malaria, tuberculosis, and cancer poses persistent hurdles given that traditional vaccine-development methods have proven to be ineffective; as such, these challenges have driven the emergence of novel vaccine design approaches. In this regard, much effort has been put into the development of new safe adjuvants and vaccine platforms. Of particular interest, the utilization of plant virus-like nanoparticles and recombinant plant viruses has gained increasing significance as an effective tool in the development of novel vaccines against infectious diseases and cancer. The present review summarizes recent advances in the use of plant viruses as nanoparticle-based vaccines and adjuvants and their mechanism of action. Harnessing plant-virus immunogenic properties will enable the design of novel, safe, and efficacious prophylactic and therapeutic vaccines against disease.

Keywords: recombinant plant virus; vaccine; adjuvant; immune response; production methods

1. Introduction

Although vaccines have allowed great achievements such as a significant reduction in incidence, mortality, and morbidity related to infectious diseases, the field of vaccinology has faced several challenges in recent years. Indeed, development of new vaccines has proven difficult especially against chronic infections or cancer. To overcome these obstacles, large research efforts are being devoted to better understand the key elements required to generate protective immunity. For example, while the majority of available vaccines mainly induce the generation of antibodies that neutralize targeted pathogens, it is now recognized that the cellular immune response is often necessary to protect against many infections. A balanced and complete immune response involving both humoral immunity, with high-affinity neutralizing antibodies limiting pathogen transmission and cellular immunity, with cytotoxic CD8⁺ T cells killing infected cells, is in fact required to control malaria, hepatitis C, and HIV/AIDS, just to list a few [1–5], highlighting the need for the development of new vaccine design approaches. Moreover, antigens and epitopes from several pathogens targeted by protective immune responses have recently been identified [6–9]. This has led to the design of safer and more specific recombinant vaccines, although they are often less immunogenic than more traditional vaccines based on live/attenuated pathogens. Therefore, the choice of vaccine formulations and the addition of suitable adjuvants will likely be required to achieve protective immunity with these novel vaccines. It is generally accepted that the best way to generate vaccines capable of generating a broad immune response with high levels of antibodies and cytotoxic T lymphocytes is to mimic a pathogenic infection while remaining as safe as possible. In this regard, virus-like nanoparticles (VLPs) have been increasingly studied in recent years with the aim of developing new effective vaccines.

2. Virus-Like Nanoparticles

VLPs mimic viruses by bearing similar protein composition while being non-infectious. In fact, most VLPs do not contain any viral genetic material while others contain nucleic acids that do not allow virus replication in mammals. For now, there are three vaccines composed of VLPs used in humans: the hepatitis B vaccine, the human papilloma vaccine, and the recently approved vaccine against hepatitis E in China [10]. These generate robust humoral immune responses but still require the addition of an adjuvant to be fully effective. Other VLPs are currently in clinical trials [11–13] and many more are in development [14–16]. The increase in VLP use in the development of novel vaccines is related to their numerous qualities that meet new medical needs. For example, their highly ordered and repetitive structures facilitate recognition by the immune system and induce B-cell activation through B-cell receptor (BCR) cross-linking [17]. The size of VLPs is generally between 20 and 300 nm, which is ideal to be effectively recognized by dendritic cells (DCs) or other antigen-presenting cells (APC) [18–21]. In addition, VLPs frequently display various Pathogen Associated Molecular Patterns (PAMPs) that are recognized by Pattern Recognition Receptors (PRRs), leading to the activation of the innate immune system and cytokine production such as type I interferon (IFN-I); notably, these cytokines were reported to increase the cross-presentation capacity of DCs and are beneficial towards cell-mediated, T-lymphocyte immune responses [22–24]. IFN- $\alpha\beta$ can also increase the humoral response, induce isotype switching, and enhance the generation of T follicular helper cells [25,26]. Furthermore, many studies have shown

the capacity of VLPs to induce a cellular immune response, therefore permitting the development of prophylactic and therapeutic vaccines targeting CD8⁺ cytotoxic T lymphocyte (CTL) responses [27–30]. This strongly correlates with APC cross-presentation of antigens fused to VLPs to CD8⁺ T cells through a Tap- and proteasome-independent pathway [31–33]. This mechanism has also been shown to generate tumor-specific CD8⁺ T-cell responses that efficiently slow down tumor growth and increase mice survival in various models [34–36]. Importantly, non-infectious VLPs are safer than attenuated or inactivated viruses and could therefore potentially be administered to immunocompromised individuals. Finally, the use of VLPs could be advantageous for developing vaccines against viruses that are impossible or difficult to grow in culture such as the human norovirus, for example [37]. Altogether, these properties contribute to the effectiveness and usefulness of VLP vaccines.

3. Recombinant Plant Virus Particles (rPVPs)

Recombinant plant virus particles are increasingly studied as candidate vaccines. They can be classified as a subtype of VLP since they are viral particles that are non-infectious in mammals. However, most rPVPs retain their replication potential in plants, posing additional safety and environmental challenges. Nonetheless, rPVPs possess all of the advantages of VLPs and thus would allow the development of effective vaccines. Many plant viruses such as the tobacco mosaic virus (TMV), cowpea mosaic virus (CPMV), potato virus X (PVX), alfalfa mosaic virus (AIMV), and papaya mosaic virus (PapMV) (see Table 1 for more information) are currently used for the development of new vaccines. Typically, plant viruses are simple, rod shaped, or bearing icosahedral symmetry; they are composed of one or two repeated coat protein (CP) subunits and bear an RNA genome. These viruses are relatively easy to engineer, produced at low cost, and very stable, enabling storage at room temperature, which is desirable for vaccination in developing countries. CP modification of plant viruses allows dense expression of fused antigens, thereby contributing to the development of an effective immune response. Finally, while other virus platforms, such as adenovirus, suffer from platform-specific antibody development [38,39], rPVPs seem to maintain their immunogenic properties in the presence of specific antibodies [40,41]. In the following paragraphs, we will discuss the different methods of production of rPVPs for vaccination, the diverse approaches for antigen expression on their surface, and achievements made with rPVPs.

Table 1. Recombinant plant virus particles used in vaccine development.

Virus	Shape	Parameters Tested	Element of Response	References
CPMV	Icosahedral	Humoral response	Binding or neutralizing antibodies	[42–54]
			Protection against challenge	[42,43,45,47]
		Cellular response	IFN- γ production	[50,51]
		Immunomodulation	APC activation	[55]
PVX	Rod	Humoral response	Binding or neutralizing antibodies	[56–60]
			Protection against challenge	[60]
		Cellular response	CD8 ⁺ T cells activation	[57,61]
			IFN- γ production	[57,61]
			Protection against challenge	[57,61]
Immunomodulation	APC activation	[56,60]		
	Cytokine production	[60]		

Table 1. Cont.

Virus	Shape	Parameters Tested	Element of Response	References
TMV	Rod	Humoral response	Binding or neutralizing antibodies	[41,61–63]
			Protection against challenge	[41,63–66]
		Cellular response	CD8 ⁺ T cells activation	[40,67,68]
			IFN- γ production	[67]
Immunomodulation	APC activation	[40,67]		
CMV	Icosahedral	Humoral response	Binding or neutralizing antibodies	[69]
		Cellular response	CD8 ⁺ T cells activation	[69]
AIMV	Icosahedral	Humoral response	IFN- γ production	[69,70]
			Binding or neutralizing antibodies	[71,72]
PapMV	Rod	Humoral response	IFN- γ production	[72]
			Binding or neutralizing antibodies	[73–75]
		Cellular response	CD8 ⁺ T cells activation	[33,76,77]
			IFN- γ production	[33,74,76,77]
		Immunomodulation	Protection against challenge	[77]
			APC activation	[78]
			Cytokine production	[78]
BaMV	Rod	Humoral response	Protection against challenge	[78]
			APC activation	[79,80]
		Cellular response	Cytokine production	[79,80]
			Adjuvant	Vaccine jointly administered
		Humoral response	Binding or neutralizing antibodies	[82,83]
Protection against challenge	[82,83]			
TBSV	Icosahedral	Humoral response	IFN- γ production	[82]
Plum pox potyvirus	Rod	Humoral response	Protection against challenge	[82]
			Binding or neutralizing antibodies	[84]

CMV: cucumber mosaic virus; BaMV: bamboo mosaic virus; TBSV: tomato bushy stunt virus.

3.1. Production Methods

rPVP production can be achieved by several methods. Production of rPVPs using plants, such as *Nicotiana benthamiana*, *Nicotiana tabacum*, or cowpea plants, is the most widely used and can be divided into two different strategies, both starting with the production of the desired cDNA. The cDNA can then be transcribed *in vitro* and used to inoculate plants depositing the RNA transcript on abraded leaves to induce a systemic infection [64]. Another option is to transform *Agrobacterium tumefaciens* with a plasmid containing the cDNA coding for the modified viral genome and then agroinfiltrate plants to induce transient expression and generate recombinant viruses [87]. A week or two later, recombinant

viruses are then purified by different techniques [62,66,71]. Remarkably, due to the possibility of CMV production in edible vegetables, e.g., celery, lettuce, cucumber, tomato, carrot, pepper, and banana [88], plant production also advances the use of oral delivery of vaccine via ingestible plants [89,90]. This strategy would therefore reduce costs related to virus purification and eliminate the need for sterile needles and trained medical staff for vaccine administration. rPVP manufacturing *in planta* also allows for large-scale production devoid of contamination risks from human pathogens. However, a weakness of oral administration of rPVPs is related to the difficulty of controlling the amount of antigen taken by the patient and the potential development of tolerance to the antigen. In addition, genetic modifications that induce foreign antigen expression on plant virus proteins can sometimes affect viral replication, thus reducing production efficiency [88]. A new method based on transgenic plant cell suspension cultures was recently developed. This process, based on the culture of calli derived from transgenic plant lines expressing viral cDNA, allows for continuous production of large amounts of rPVPs with high reproducibility [91]. More conventional techniques are also used to produce rPVPs such as bacteria [78,92], yeast [93,94], and insect cell cultures [95,96]. Plants, bacteria, and yeast are all simple and low cost manufacturing methods. However, bacteria and yeast sometimes produce insoluble proteins, thus restricting particle self-assembly [94,97]. The less practical and more costly baculovirus expression system seems to avoid these problems [94–96]. When capsid protein production does not induce particle formation, it is also possible to perform the assembly process *in vitro*, with or without the addition of nucleic acids [78,97–99]. Although this process is more laborious, it allows for better control of the RNA present inside the particle since diverse and uncontrolled sources of RNA can be incorporated in self-assembled viral particles *in vivo* [93,94,96]. In addition, *in vitro* assembly allows for the packing of specific RNA transcripts in recombinant plant virus capsid proteins that will further induce *in vivo* gene expression [100]. Atabekov and colleagues generated spherical nanoparticles using thermal denaturation of the TMV CP protein [101]. These particles are devoid of RNA and can bind different proteins or peptides, making it a universal and immunogenic particle platform [102]. Therefore, these different manufacturing processes generate rPVPs that either contain no RNA, host RNA, viral RNA, or inactive or replicative synthetic RNA. Plant virus particles are most probably safe enough for administration in humans, but many are still infectious in plants. Therefore, inactivation methods based on chemical treatment or UV irradiation, for example, were developed to ensure that rPVPs are innocuous [43,103,104]. Finally, methods using eukaryotic cells have the advantage of allowing post-transcriptional modifications ensuring that the rPVP is more similar to the parental virus and more stable [93,94]. In summary several manufacturing processes have been developed to efficiently produce the desired rPVP, each with their advantages and drawbacks.

3.2. Antigen Expression on rPVPs

Several processes lead to the expression of foreign antigens on rPVPs. The most commonly used are molecular cloning techniques to fuse sequences coding for the antigen directly within the CP gene construct. In the case of icosahedral viruses such as CMV, CPMV, and AIMV, localization within sequences exposed on the viral surface as well as sites accepting peptide fusions have been well studied [88,105]. In general, insertions of 10–50 amino acids are well tolerated and are structured in closed loops exposed on the surface of the virus. For example, most successful fusions with CPMV were achieved by inserting

epitopes within loops between amino acids 22 and 23 of the S protein [43,46,51]. Nevertheless, others have managed to obtain stable particles using N-terminal or C-terminal fusions with AIMV and TBSV, respectively, even if the N-terminal region is known to be important for particle formation for some icosahedral viruses [71,96]. However, in some cases, only 20%–30% of rPVP CPs express the fused antigen [71]. In the case of rod-shaped viruses, N-terminal and C-terminal fusions are the most commonly used [56,57,64,74,77]. This allows surface expression without causing destabilization of the structure. In addition, specific and well-defined sites in the CP sequence, other than the C- and N-termini, were also shown to accept fusion without destabilization while allowing surface expression of fused antigens and recognition by the immune system [106–108]. However, the tolerated size of peptides fused to rod-shaped viruses is usually more restricted [58,109]. Therefore, in order to fuse bigger peptides or complete proteins, fusion processes other than molecular cloning have been developed. One such technique consists in biotinylating the CP to attach streptavidin-linked proteins or peptides [60,62]. Others also incorporate a reactive lysine in the sequence of the CP to chemically conjugate peptides using a heterobifunctional linker [67,68,100] or perform copper catalyzed azide-alkyne cycloaddition to covalently link antigens to the viral capsid [52,110]. Spontaneous conjugation due to electrostatic and/or hydrophobic interactions between foreign antigens and viral CP can also happen and are further stabilized by formaldehyde treatment [101,102]. However, antigen insertion may potentially induce viral particle destabilization [70,109,111,112]. Apart from the size and the localization of the peptide, its charge and isoelectric point can also impact the particles' capacity to assemble [109,112,113]. In some cases, the generation of mixed particles allows for the formation of stable rPVPs [60]. For example, in order to avoid interference with particle assembly, the insertion of the foot-and-mouth disease virus 2A peptide in the cDNA construct of PVX benefits from a ribosomal skipping process to produce mixed particles made of recombinant and wild-type CPs [58,59]. Finally, the localization of conjugated antigens may also affect the ability to elicit an immune response against fused antigens by influencing the accessibility and conformation of the antigen and thus the immunogenicity of the rPVP [54,110,111]. In summary, with new techniques developed and a better comprehension of factors influencing the stability and immunogenicity of rPVPs, we are better equipped to generate effective vaccines and it is now possible to conjugate very large peptides [59,114] or even complete protein antigens to such particles [62].

3.3. rPVPs as Vaccines to Induce Humoral Immune Responses

Most of the currently used vaccines induce a humoral response upon administration, which will then protect individuals against infection or the appearance of disease (reviewed in [115]). As it is the case for current vaccines, plant viruses used as vaccine platforms are also able to trigger the production of antibodies. Not only are these platforms able to induce IgGs, mainly found in serum after sub-cutaneous, intra-peritoneal, and to some extent intra-nasal injections, IgAs are also found in mucosa after intra-nasal and oral administration [44,50,51,53,56]. Plant viruses used as carriers for foreign epitopes can therefore efficiently induce the production of both systemic and mucosal antibodies following administration by various routes, which broadens their potential targets since not all pathogens will require the same antibody response to be cleared from the host. The structure of epitopes presented on the surface of rPVPs will depend on their localization and size. When in an optimal localization, epitopes will adopt a

structure similar to their native conformation, allowing antibodies to recognize the virus or bacteria against which they were mounted [54,59]. As such, antibodies from HCV-infected patients were able to recognize a CMV engineered virus expressing the R9 peptide from HCV [70], even though these patients were never exposed to the rPVP. rPVP-based experimental vaccines were also shown to be as effective or even more effective at inducing an antibody response compared to commercially available vaccines [83], peptides alone [61,62,73–75], or peptides conjugated to keyhole limpet haemocyanin (KLH) [43,51]. Moreover, these vaccines are often administered in conjunction with less toxic adjuvants, compared to Freund's Complete Adjuvant (which is not approved for human use), like QS-21 and QuilA (saponin-based) or RIBI [47,48,64], or even without the use of any adjuvant [44,56,57]. Plant viruses also often require less peptide to induce efficient antibody responses compared to commercially available vaccines or peptides conjugated to KLH [41,46].

Immunization in different experimental animal models not only generated specific antibodies but also protected against challenge with various viruses, bacteria, or tumor cell lines when epitopes were presented on CPMV [42,43,45,48,116], PVX [60,61], Bamboo Mosaic Virus (BaMV) [82,83], or TMV [41,63–66]. Protection against challenge (sometimes lethal) is thought to be partially achieved by neutralizing antibodies, generated following immunization with engineered CPMV [43,47,51,56,85], PVX [56], and Plum Pox Potyvirus [85]. This protection can be broadened to various strains and species of the same pathogen using conserved epitopes, which are usually weakly immunogenic. When such epitopes are presented on the surface of rPVPs, their immunogenicity is increased, allowing for the production of a more effective antibody response and therefore a broader protection of the host [41,49,110]. This has been demonstrated for peptides 10 and 18 of the outer membrane protein F of *Pseudomonas aeruginosa* presented at the surface of CPMV [45,117], as well as for the R9 peptide of HCV presented on PVX [58]. This broad recognition was also observed when mannose was engineered to be displayed on CPMV inducing antibodies interacting with various of its analogues and derivatives [52].

Part of the mechanism by which plant virus carriers induce the production of antibodies is hypothesized to proceed through cross-linking of the BCR [49]. The presentation of many epitopes in close proximity might favor such cross-linking, leading to the proliferation of B lymphocytes, presentation of epitopes to T cells, and differentiation of B lymphocytes into antibody-producing plasma cells [17]. In agreement with this, Nicholas *et al.* demonstrated that higher antigen expression on the surface of CPMV particles provided a better immune response [51]. It also explains why viral platforms seem more efficient at inducing antibodies than peptide-KLH conjugates, for example [43,51].

3.4. rPVPs as Vaccines to Induce Cellular Immune Responses

Even though antibodies generated following vaccination are often sufficient to protect against some diseases, elicitation of both cellular and humoral adaptive immune responses is sometimes necessary for protection (reviewed in [115]). The use of plant viruses as epitope carriers has proven effective in inducing cellular immune responses directed towards antigens presented on the particle. We have demonstrated that epitopes fused to the PapMV platform were able to induce the activation of CD8⁺ T cells by a, cross-presentation pathway [33,76,77]. Other rPVPs, such as TMV [40,67,68], CMV [69], CPMV [47] and PVX [57,61] were also shown to generate and enhance CD8⁺ T cell-mediated immune responses against fused epitopes. The main correlate for induction of effective T-cell responses seems to be production

of IFN- γ . IFN- γ production was observed when peripheral blood mononuclear cells (PBMCs) from healthy patients or patients infected with HCV were incubated with AlMV expressing a respiratory syncytial virus epitope [72] or CMV expressing the R9 epitope from HCV [69,70], both demonstrating that human PBMCs can be activated by rPVPs, while the latter also demonstrates that the epitope is efficiently processed and presented, leading to the potent activation of CD8⁺ T cells (*i.e.*, IFN- γ production). Cellular immune responses also correlated with protection against challenge with tumor cell lines B16-OVA and Eg.7-OVA [67], Lymphocytic Choriomeningitis Virus [77], and Foot and Mouth Disease Virus [84].

3.5. rPVPs Used as Immunomodulators and Adjuvants

In order to generate an effective immune response, APCs must be activated and present antigens to cells of the adaptive immune system [118]. As previously mentioned, rPVPs possess many suitable characteristics for them to be taken up by APCs, processed, and presented to T cells. Indeed, DCs were shown to be activated following TMV [40,67], PVX [56,60], CPMV [55], and PapMV [77,79,80] immunization. Activated DCs upregulate various co-stimulatory molecules such as CD40, CD86, CD80, MHCII, MHCI, and CCR7 [60,79] and also produce pro-inflammatory cytokines such as IL-12, TNF- α , IL-6, and IFN- α [60,78–81]. DCs are not the only cell population that was shown to be activated following immunization with rPVPs since B lymphocytes, macrophages, and NK cells can also upregulate activation markers following rPVP encounter [55,80].

Since rPVPs can be efficiently taken up by APCs and induce their activation, they can potentially be used as adjuvants to enhance the effectiveness of concomitantly administered vaccines. We have indeed demonstrated that PapMV can be used as an adjuvant in combination with various types of vaccines. When PapMV was administered jointly with bone marrow-derived DCs presenting OVA, cellular immune responses towards OVA were enhanced, leading to better protection against a *Listeria monocytogenes*-OVA challenge in mice [79]. Similar protection was observed when PapMV was administered in mice in concert with the seasonal trivalent influenza vaccine (TIV) [81]. When used as an adjuvant, PapMV was also shown to enhance the production of antibodies directed against TIV [73,80,81]. PapMV has also been shown to be able to prime the immune system and protect mice from an influenza infection on its own, without being fused to an epitope or being administered with a separate vaccine [78]. Finally, it was shown to induce a broader immune response against TIV antigens, providing protection against strains of influenza not contained within the vaccine [81]. To our knowledge, PapMV is the first rPVP used as an adjuvant or an immunomodulator specifically to prime the immune system.

The mechanisms by which rPVPs activate APCs are slowly being uncovered. We have identified one such mechanism in the PapMV system as being the recognition of nucleic acid found within rPVPs that induces APC activation. Single-stranded RNA (ssRNA) within PapMV particles is in fact recognized by TLR7 in endosomes of APCs, mainly plasmacytoid DCs, leading to the production of IFN- α [60,79]. The lack of activation of murine splenocytes upon administration of PapMV monomers further illustrates the importance of ssRNA for its adjuvancy properties [79]. Of note, despite RNA serving as the major immunomodulatory molecule following PapMV administration, the use of RNA alone cannot replace rPVPs since it would be rapidly degraded following administration due to the abundance of host RNAses

found within the blood or other bodily fluids. The viral capsid therefore provides protection from degradation to the RNA molecule, allowing it to be efficiently delivered to endosomes. Plant virus particles thus carry their adjuvant properties inside a protective capsid [80], explaining their versatility both as vaccines and adjuvants.

4. Conclusions and Perspectives for rPVPs

Although there is still much research to be done before rPVPs are used as vaccines in humans, great achievements have been made in recent years in this field. Several production and antigen expression methods have been developed and improved, thus leading to the generation of many promising candidate vaccines. Beyond demonstrating that rPVPs are effective platforms to generate both humoral and cellular immune responses against fused antigens, we now know that rPVPs are efficiently recognized by the immune system of mammals, which efficiently activates the innate immune system. Therefore, rPVPs possess attractive intrinsic adjuvant properties that can be used for immunomodulatory purposes. This has important implications for future vaccine design and opens the door for new applications. A strong testimony to the recent achievements made in using rPVPs as novel vaccines is the recent entry of two rPVPs in clinical trials, PapMV as an adjuvant for the influenza vaccine [119] and AIMV as a vaccine against malaria [120]. In light of this, it seems very likely that in the near future plant viruses will be used in humans to address unmet medical needs as prophylactic and therapeutic vaccines and immunomodulators against infection or cancer.

Acknowledgments

This work was financially supported by Canadian Institutes of Health Research Grant MOP-89833 and the Jeanne and J.-Louis Lévesque Chair in Immunovirology from the J.-Louis Lévesque Foundation. Marie-Ève Lebel and Karine Chartrand acknowledge studentship support from the Fonds de Recherche Santé Québec.

Author Contributions

Marie-Ève Lebel, Karine Chartrand, Denis Leclerc, and Alain Lamarre wrote the manuscript.

Conflict of Interest

Denis Leclerc is the founder and a shareholder of Folia Biotech, a startup company with the mandate to commercialize the PapMV nanoparticle technology.

References

1. Imai, T.; Ishida, H.; Suzue, K.; Taniguchi, T.; Okada, H.; Shimokawa, C.; Hisaeda, H. Cytotoxic activities of CD8⁺ T cells collaborate with macrophages to protect against blood-stage murine malaria. *Elife* **2015**, doi:10.7554/eLife.04232.
2. Barth, H.; Rybczynska, J.; Patient, R.; Choi, Y.; Sapp, R.K.; Baumert, T.F.; Krawczynski, K.; Liang, T.J. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. *Hepatology* **2011**, *54*, 1135–1148.

3. Holz, L.; Rehmann, B. T cell responses in hepatitis C virus infection: Historical overview and goals for future research. *Antivir. Res.* **2015**, *114*, 96–105.
4. Pereyra, F.; Heckerman, D.; Carlson, J.M.; Kadie, C.; Soghoian, D.Z.; Karel, D.; Goldenthal, A.; Davis, O.B.; de Ziel, C.E.; Lin, T.; *et al.* Hiv control is mediated in part by CD8⁺ T-cell targeting of specific epitopes. *J. Virol.* **2014**, *88*, 12937–12948.
5. De Souza, J.B. Protective immunity against malaria after vaccination. *Parasite Immunol.* **2014**, *36*, 131–139.
6. Chakraborty, S.; Rahman, T.; Chakravorty, R. Characterization of the protective HIV-1 CTL epitopes and the corresponding HLA class I alleles: A step towards designing CTL based HIV-1 vaccine. *Adv. Virol.* **2014**, doi:10.1155/2014/321974.
7. Hafalla, J.C.; Bauza, K.; Friesen, J.; Gonzalez-Aseguinolaza, G.; Hill, A.V.; Matuschewski, K. Identification of targets of CD8⁺ T cell responses to malaria liver stages by genome-wide epitope profiling. *PLoS Pathog.* **2013**, *9*, e1003303.
8. Linnemann, C.; van Buuren, M.M.; Bies, L.; Verdegaal, E.M.; Schotte, R.; Calis, J.J.; Behjati, S.; Velds, A.; Hilkmann, H.; Atmioui, D.E.; *et al.* High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4⁺ T cells in human melanoma. *Nat. Med.* **2015**, *21*, 81–85.
9. Frosig, T.M.; Lyngaa, R.; Met, O.; Larsen, S.K.; Donia, M.; Svane, I.M.; Thor Straten, P.; Hadrup, S.R. Broadening the repertoire of melanoma-associated T-cell epitopes. *Cancer Immunol. Immunother.* **2015**, *64*, 609–620.
10. Riedmann, E.M. Chinese biotech partnership brings first hepatitis E vaccine to the market. *Hum. Vaccines Immunother.* **2012**, *8*, 1743–1744.
11. Safety and immunogenicity of norovirus bivalent virus-like particle vaccine in healthy adults. Available online: <https://clinicaltrials.gov/ct2/show/NCT02142504> (accessed on 11 July 2015).
12. Trial to evaluate safety and immunogenicity of trivalent seasonal influenza virus-like particle (VLP) vaccine (recombinant). Available online: <https://clinicaltrials.gov/ct2/show/NCT00903552> (accessed on 11 July 2015).
13. Immunogenicity, safety and tolerability of a plant-derived seasonal virus-like-particle quadrivalent influenza vaccine in adults. Available online: <https://clinicaltrials.gov/ct2/show/NCT02233816> (accessed on 11 July 2015).
14. Sun, S.; Gao, F.; Mao, Q.; Shao, J.; Jiang, L.; Liu, D.; Wang, Y.; Yao, X.; Wu, X.; Sun, B.; *et al.* Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice. *Hum. Vaccines Immunother.* **2015**, doi:10.1080/21645515.2015.1053675.
15. Kim, M.C.; Song, J.M.; O, E.; Kwon, Y.M.; Lee, Y.J.; Compans, R.W.; Kang, S.M. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. *Mol. Ther.* **2013**, *21*, 485–492.
16. Kim, S.H.; Chen, S.; Jiang, X.; Green, K.Y.; Samal, S.K. Immunogenicity of newcastle disease virus vectors expressing norwalk virus capsid protein in the presence or absence of VP2 protein. *Virology* **2015**, *484*, 163–169.
17. Batista, F.D.; Harwood, N.E. The who, how and where of antigen presentation to B cells. *Nat. Rev. Immunol.* **2009**, *9*, 15–27.

18. Fifis, T.; Gamvrellis, A.; Crimeen-Irwin, B.; Pietersz, G.A.; Li, J.; Mottram, P.L.; McKenzie, I.F.; Plebanski, M. Size-dependent immunogenicity: Therapeutic and protective properties of nano-vaccines against tumors. *J. Immunol.* **2004**, *173*, 3148–3154.
19. Li, X.; Sloat, B.R.; Yanasarn, N.; Cui, Z. Relationship between the size of nanoparticles and their adjuvant activity: Data from a study with an improved experimental design. *Eur. J. Pharm. Biopharm.* **2011**, *78*, 107–116.
20. Li, X.; Aldayel, A.M.; Cui, Z. Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles. *J. Control. Release* **2014**, *173*, 148–157.
21. Bershteyn, A.; Hanson, M.C.; Crespo, M.P.; Moon, J.J.; Li, A.V.; Suh, H.; Irvine, D.J. Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. *J. Control. Release* **2012**, *157*, 354–365.
22. Le Bon, A.; Durand, V.; Kamphuis, E.; Thompson, C.; Bulfone-Paus, S.; Rossmann, C.; Kalinke, U.; Tough, D.F. Direct stimulation of t cells by type I IFN enhances the CD8⁺ T cell response during cross-priming. *J. Immunol.* **2006**, *176*, 4682–4689.
23. Kolumam, G.A.; Thomas, S.; Thompson, L.J.; Sprent, J.; Murali-Krishna, K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. *J. Exp. Med.* **2005**, *202*, 637–650.
24. Le Bon, A.; Etchart, N.; Rossmann, C.; Ashton, M.; Hou, S.; Gewert, D.; Borrow, P.; Tough, D.F. Cross-priming of CD8⁺ T cells stimulated by virus-induced type I interferon. *Nat. Immunol.* **2003**, *4*, 1009–1015.
25. Le Bon, A.; Schiavoni, G.; D'Agostino, G.; Gresser, I.; Belardelli, F.; Tough, D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells *in vivo*. *Immunity* **2001**, *14*, 461–470.
26. Cucak, H.; Yrlid, U.; Reizis, B.; Kalinke, U.; Johansson-Lindbom, B. Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. *Immunity* **2009**, *31*, 491–501.
27. Kammer, A.R.; Amacker, M.; Rasi, S.; Westerfeld, N.; Gremion, C.; Neuhaus, D.; Zurbriggen, R. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. *Vaccine* **2007**, *25*, 7065–7074.
28. Cubas, R.; Zhang, S.; Kwon, S.; Sevick-Muraca, E.M.; Li, M.; Chen, C.; Yao, Q. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. *J. Immunother.* **2009**, *32*, 118–128.
29. Pinto, L.A.; Viscidi, R.; Harro, C.D.; Kemp, T.J.; Garcia-Pineros, A.J.; Trivett, M.; Demuth, F.; Lowy, D.R.; Schiller, J.T.; Berzofsky, J.A.; *et al.* Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. *Virology* **2006**, *353*, 451–462.
30. Quan, F.S.; Huang, C.; Compans, R.W.; Kang, S.M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. *J. Virol.* **2007**, *81*, 3514–3524.
31. Win, S.J.; Ward, V.K.; Dunbar, P.R.; Young, S.L.; Baird, M.A. Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. *Immunol. Cell Biol.* **2011**, *89*, 681–688.

32. Ruedl, C.; Storni, T.; Lechner, F.; Bachi, T.; Bachmann, M.F. Cross-presentation of virus-like particles by skin-derived CD8⁺ dendritic cells: A dispensable role for tap. *Eur. J. Immunol.* **2002**, *32*, 818–825.
33. Leclerc, D.; Beauseigle, D.; Denis, J.; Morin, H.; Pare, C.; Lamarre, A.; Lapointe, R. Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells. *J. Virol.* **2007**, *81*, 1319–1326.
34. Peacey, M.; Wilson, S.; Perret, R.; Ronchese, F.; Ward, V.K.; Young, V.; Young, S.L.; Baird, M.A. Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response. *Vaccine* **2008**, *26*, 5334–5337.
35. Cubas, R.; Zhang, S.; Li, M.; Chen, C.; Yao, Q. Chimeric trop2 virus-like particles: A potential immunotherapeutic approach against pancreatic cancer. *J. Immunother.* **2011**, *34*, 251–263.
36. Speiser, D.E.; Schwarz, K.; Baumgaertner, P.; Manolova, V.; Devevre, E.; Sterry, W.; Walden, P.; Zippelius, A.; Conzett, K.B.; Senti, G.; *et al.* Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. *J. Immunother.* **2010**, *33*, 848–858.
37. Ma, Y.; Li, J. Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: A new vaccine candidate against an important noncultivable virus. *J. Virol.* **2011**, *85*, 2942–2952.
38. Zaiss, A.K.; Machado, H.B.; Herschman, H.R. The influence of innate and pre-existing immunity on adenovirus therapy. *J. Cell. Biochem.* **2009**, *108*, 778–790.
39. Fausther-Bovendo, H.; Kobinger, G.P. Pre-existing immunity against AD vectors: Humoral, cellular, and innate response, what's important? *Hum. Vaccines Immunother.* **2014**, *10*, 2875–2884.
40. Kemnade, J.O.; Seethammagari, M.; Collinson-Pautz, M.; Kaur, H.; Spencer, D.M.; McCormick, A.A. Tobacco mosaic virus efficiently targets DC uptake, activation and antigen-specific T cell responses *in vivo*. *Vaccine* **2014**, *32*, 4228–4233.
41. Mallajosyula, J.K.; Hiatt, E.; Hume, S.; Johnson, A.; Jeevan, T.; Chikwamba, R.; Pogue, G.P.; Bratcher, B.; Haydon, H.; Webby, R.J.; *et al.* Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge. *Hum. Vaccines Immunother.* **2014**, *10*, 586–595.
42. Dalsgaard, K.; Uttenthal, A.; Jones, T.D.; Xu, F.; Merryweather, A.; Hamilton, W.D.; Langeveld, J.P.; Boshuizen, R.S.; Kamstrup, S.; Lomonossoff, G.P.; *et al.* Plant-derived vaccine protects target animals against a viral disease. *Nat. Biotechnol.* **1997**, *15*, 248–252.
43. Langeveld, J.P.; Brennan, F.R.; Martinez-Torrecuadrada, J.L.; Jones, T.D.; Boshuizen, R.S.; Vela, C.; Casal, J.I.; Kamstrup, S.; Dalsgaard, K.; Meloen, R.H.; *et al.* Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus. *Vaccine* **2001**, *19*, 3661–3670.
44. Brennan, F.R.; Bellaby, T.; Helliwell, S.M.; Jones, T.D.; Kamstrup, S.; Dalsgaard, K.; Flock, J.I.; Hamilton, W.D. Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice. *J. Virol.* **1999**, *73*, 930–938.
45. Brennan, F.R.; Gilleland, L.B.; Staczek, J.; Bendig, M.M.; Hamilton, W.D.; Gilleland, H.E., Jr. A chimaeric plant virus vaccine protects mice against a bacterial infection. *Microbiology* **1999**, *145*, 2061–2067.
46. Brennan, F.R.; Jones, T.D.; Longstaff, M.; Chapman, S.; Bellaby, T.; Smith, H.; Xu, F.; Hamilton, W.D.; Flock, J.I. Immunogenicity of peptides derived from a fibronectin-binding protein of *S. Aureus* expressed on two different plant viruses. *Vaccine* **1999**, *17*, 1846–1857.

47. McInerney, T.L.; Brennan, F.R.; Jones, T.D.; Dimmock, N.J. Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide. *Vaccine* **1999**, *17*, 1359–1368.
48. Rennermalm, A.; Li, Y.H.; Bohaufs, L.; Jarstrand, C.; Brauner, A.; Brennan, F.R.; Flock, J.I. Antibodies against a truncated *Staphylococcus aureus* fibronectin-binding protein protect against dissemination of infection in the rat. *Vaccine* **2001**, *19*, 3376–3383.
49. Miermont, A.; Barnhill, H.; Strable, E.; Lu, X.; Wall, K.A.; Wang, Q.; Finn, M.G.; Huang, X. Cowpea mosaic virus capsid: A promising carrier for the development of carbohydrate based antitumor vaccines. *Chemistry* **2008**, *14*, 4939–4947.
50. Nicholas, B.L.; Brennan, F.R.; Hamilton, W.D.; Wakelin, D. Effect of priming/booster immunisation protocols on immune response to canine parvovirus peptide induced by vaccination with a chimaeric plant virus construct. *Vaccine* **2003**, *21*, 2441–2447.
51. Nicholas, B.L.; Brennan, F.R.; Martinez-Torrecedrada, J.L.; Casal, J.I.; Hamilton, W.D.; Wakelin, D. Characterization of the immune response to canine parvovirus induced by vaccination with chimaeric plant viruses. *Vaccine* **2002**, *20*, 2727–2734.
52. Kaltgrad, E.; Sen Gupta, S.; Punna, S.; Huang, C.Y.; Chang, A.; Wong, C.H.; Finn, M.G.; Blixt, O. Anti-carbohydrate antibodies elicited by polyvalent display on a viral scaffold. *Chembiochem* **2007**, *8*, 1455–1462.
53. Durrani, Z.; McInerney, T.L.; McLain, L.; Jones, T.; Bellaby, T.; Brennan, F.R.; Dimmock, N.J. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. *J. Immunol. Methods* **1998**, *220*, 93–103.
54. Taylor, K.M.; Lin, T.; Porta, C.; Mosser, A.G.; Giesing, H.A.; Lomonosoff, G.P.; Johnson, J.E. Influence of three-dimensional structure on the immunogenicity of a peptide expressed on the surface of a plant virus. *J. Mol. Recognit.* **2000**, *13*, 71–82.
55. Gonzalez, M.J.; Plummer, E.M.; Rae, C.S.; Manchester, M. Interaction of cowpea mosaic virus (CPMV) nanoparticles with antigen presenting cells *in vitro* and *in vivo*. *PLoS ONE* **2009**, *4*, e7981.
56. Marusic, C.; Rizza, P.; Lattanzi, L.; Mancini, C.; Spada, M.; Belardelli, F.; Benvenuto, E.; Capone, I. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. *J. Virol.* **2001**, *75*, 8434–8439.
57. Lico, C.; Mancini, C.; Italiani, P.; Betti, C.; Boraschi, D.; Benvenuto, E.; Baschieri, S. Plant-produced potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8+ T cells in mice. *Vaccine* **2009**, *27*, 5069–5076.
58. Uhde-Holzem, K.; Schlosser, V.; Viazov, S.; Fischer, R.; Commandeur, U. Immunogenic properties of chimeric potato virus X particles displaying the hepatitis C virus hypervariable region I peptide R9. *J. Virol. Methods* **2010**, *166*, 12–20.
59. Marconi, G.; Albertini, E.; Barone, P.; de Marchis, F.; Lico, C.; Marusic, C.; Rutili, D.; Veronesi, F.; Porceddu, A. In planta production of two peptides of the classical swine fever virus (CSFV) E2 glycoprotein fused to the coat protein of potato virus X. *BMC Biotechnol.* **2006**, doi:10.1186/1472-6750-6-29.

60. Jobsri, J.; Allen, A.; Rajagopal, D.; Shipton, M.; Kanyuka, K.; Lomonossoff, G.P.; Ottensmeier, C.; Diebold, S.S.; Stevenson, F.K.; Savelyeva, N. Plant virus particles carrying tumour antigen activate TLR7 and induce high levels of protective antibody. *PLoS ONE* **2015**, *10*, e0118096.
61. Massa, S.; Simeone, P.; Muller, A.; Benvenuto, E.; Venuti, A.; Franconi, R. Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. *Hum. Gene Ther.* **2008**, *19*, 354–364.
62. Smith, M.L.; Lindbo, J.A.; Dillard-Telm, S.; Brosio, P.M.; Lasnik, A.B.; McCormick, A.A.; Nguyen, L.V.; Palmer, K.E. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. *Virology* **2006**, *348*, 475–488.
63. Jiang, L.; Li, Q.; Li, M.; Zhou, Z.; Wu, L.; Fan, J.; Zhang, Q.; Zhu, H.; Xu, Z. A modified tmv-based vector facilitates the expression of longer foreign epitopes in tobacco. *Vaccine* **2006**, *24*, 109–115.
64. Palmer, K.E.; Benko, A.; Doucette, S.A.; Cameron, T.I.; Foster, T.; Hanley, K.M.; McCormick, A.A.; McCulloch, M.; Pogue, G.P.; Smith, M.L.; *et al.* Protection of rabbits against CUTANEOUS papillomavirus infection using recombinant tobacco mosaic virus containing 12 capsid epitopes. *Vaccine* **2006**, *24*, 5516–5525.
65. Staczek, J.; Bendahmane, M.; Gilleland, L.B.; Beachy, R.N.; Gilleland, H.E., Jr. Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein f of *Pseudomonas aeruginosa* provides protection against challenge with *P. aeruginosa*. *Vaccine* **2000**, *18*, 2266–2274.
66. Koo, M.; Bendahmane, M.; Lettieri, G.A.; Paoletti, A.D.; Lane, T.E.; Fitch, J.H.; Buchmeier, M.J.; Beachy, R.N. Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 7774–7779.
67. McCormick, A.A.; Corbo, T.A.; Wykoff-Clary, S.; Nguyen, L.V.; Smith, M.L.; Palmer, K.E.; Pogue, G.P. Tmv-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models. *Vaccine* **2006**, *24*, 6414–6423.
68. McCormick, A.A.; Corbo, T.A.; Wykoff-Clary, S.; Palmer, K.E.; Pogue, G.P. Chemical conjugate tmv-peptide bivalent fusion vaccines improve cellular immunity and tumor protection. *Bioconjug. Chem.* **2006**, *17*, 1330–1338.
69. Piazzolla, G.; Nuzzaci, M.; Tortorella, C.; Panella, E.; Natilla, A.; Boscia, D.; de Stradis, A.; Piazzolla, P.; Antonaci, S. Immunogenic properties of a chimeric plant virus expressing A hepatitis C virus (HCV)-derived epitope: New prospects for an HCV vaccine. *J. Clin. Immunol.* **2005**, *25*, 142–152.
70. Nuzzaci, M.; Piazzolla, G.; Vitti, A.; Lapelosa, M.; Tortorella, C.; Stella, I.; Natilla, A.; Antonaci, S.; Piazzolla, P. Cucumber mosaic virus as a presentation system for a double hepatitis C virus-derived epitope. *Arch. Virol.* **2007**, *152*, 915–928.
71. Jones, R.M.; Chichester, J.A.; Mett, V.; Jaje, J.; Tottey, S.; Manceva, S.; Casta, L.J.; Gibbs, S.K.; Musiychuk, K.; Shamloul, M.; *et al.* A plant-produced PFS25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against *Plasmodium falciparum* in immunized mice. *PLoS ONE* **2013**, *8*, e79538.

72. Yusibov, V.; Mett, V.; Mett, V.; Davidson, C.; Musiychuk, K.; Gilliam, S.; Farese, A.; Macvittie, T.; Mann, D. Peptide-based candidate vaccine against respiratory syncytial virus. *Vaccine* **2005**, *23*, 2261–2265.
73. Denis, J.; Acosta-Ramirez, E.; Zhao, Y.; Hamelin, M.E.; Koukavica, I.; Baz, M.; Abed, Y.; Savard, C.; Pare, C.; Lopez Macias, C.; *et al.* Development of a universal influenza a vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. *Vaccine* **2008**, *26*, 3395–3403.
74. Babin, C.; Majeau, N.; Leclerc, D. Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP. *J. Nanobiotechnol.* **2013**, doi:10.1186/1477-3155-11-10.
75. Denis, J.; Majeau, N.; Acosta-Ramirez, E.; Savard, C.; Bedard, M.C.; Simard, S.; Lecours, K.; Bolduc, M.; Pare, C.; Willems, B.; *et al.* Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: Evidence for the critical function of multimerization. *Virology* **2007**, *363*, 59–68.
76. Hanafi, L.A.; Bolduc, M.; Gagne, M.E.; Dufour, F.; Langelier, Y.; Boulassel, M.R.; Routy, J.P.; Leclerc, D.; Lapointe, R. Two distinct chimeric potexviruses share antigenic cross-presentation properties of mhc class I epitopes. *Vaccine* **2010**, *28*, 5617–5626.
77. Lacasse, P.; Denis, J.; Lapointe, R.; Leclerc, D.; Lamarre, A. Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation. *J. Virol.* **2008**, *82*, 785–794.
78. Mathieu, C.; Rioux, G.; Dumas, M.C.; Leclerc, D. Induction of innate immunity in lungs with virus-like nanoparticles leads to protection against influenza and *Streptococcus pneumoniae* challenge. *Nanomed. Nanotechnol. Biol. Med.* **2013**, *9*, 839–848.
79. Lebel, M.E.; Daudelin, J.F.; Chartrand, K.; Tarrab, E.; Kalinke, U.; Savard, P.; Labrecque, N.; Leclerc, D.; Lamarre, A. Nanoparticle adjuvant sensing by TLR7 enhances CD8+ T cell-mediated protection from listeria monocytogenes infection. *J. Immunol.* **2014**, *192*, 1071–1078.
80. Acosta-Ramirez, E.; Perez-Flores, R.; Majeau, N.; Pastelin-Palacios, R.; Gil-Cruz, C.; Ramirez-Saldana, M.; Manjarrez-Orduno, N.; Cervantes-Barragan, L.; Santos-Argumedo, L.; Flores-Romo, L.; *et al.* Translating innate response into long-lasting antibody response by the intrinsic antigen-adjuvant properties of papaya mosaic virus. *Immunology* **2008**, *124*, 186–197.
81. Savard, C.; Guerin, A.; Drouin, K.; Bolduc, M.; Laliberte-Gagne, M.E.; Dumas, M.C.; Majeau, N.; Leclerc, D. Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. *PLoS ONE* **2011**, *6*, e21522.
82. Yang, C.D.; Liao, J.T.; Lai, C.Y.; Jong, M.H.; Liang, C.M.; Lin, Y.L.; Lin, N.S.; Hsu, Y.H.; Liang, S.M. Induction of protective immunity in swine by recombinant bamboo mosaic virus expressing foot-and-mouth disease virus epitopes. *BMC Biotechnol.* **2007**, doi:10.1186/1472-6750-7-62.
83. Chen, T.H.; Chen, T.H.; Hu, C.C.; Liao, J.T.; Lee, C.W.; Liao, J.W.; Lin, M.Y.; Liu, H.J.; Wang, M.Y.; Lin, N.S.; *et al.* Induction of protective immunity in chickens immunized with plant-made chimeric bamboo mosaic virus particles expressing very virulent infectious bursal disease virus antigen. *Virus Res.* **2012**, *166*, 109–115.
84. Joelson, T.; Akerblom, L.; Oxelfelt, P.; Strandberg, B.; Tomenius, K.; Morris, T.J. Presentation of a foreign peptide on the surface of tomato bushy stunt virus. *J. Gen. Virol.* **1997**, *78*, 1213–1217.
85. Fernandez-Fernandez, M.R.; Martinez-Torrecedrada, J.L.; Casal, J.I.; Garcia, J.A. Development of an antigen presentation system based on plum pox potyvirus. *FEBS Lett.* **1998**, *427*, 229–235.

86. Fernandez-Fernandez, M.R.; Martinez-Torrecuadrada, J.L.; Roncal, F.; Dominguez, E.; Garcia, J.A. Identification of immunogenic hot spots within plum pox potyvirus capsid protein for efficient antigen presentation. *J. Virol.* **2002**, *76*, 12646–12653.
87. Petukhova, N.V.; Gasanova, T.V.; Ivanov, P.A.; Atabekov, J.G. High-level systemic expression of conserved influenza epitope in plants on the surface of rod-shaped chimeric particles. *Viruses* **2014**, *6*, 1789–1800.
88. Natilla, A.; Piazzolla, G.; Nuzzaci, M.; Saldarelli, P.; Tortorella, C.; Antonaci, S.; Piazzolla, P. Cucumber mosaic virus as carrier of a hepatitis C virus-derived epitope. *Arch. Virol.* **2004**, *149*, 137–154.
89. Thanavala, Y.; Mahoney, M.; Pal, S.; Scott, A.; Richter, L.; Natarajan, N.; Goodwin, P.; Arntzen, C.J.; Mason, H.S. Immunogenicity in humans of an edible vaccine for hepatitis B. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 3378–3382.
90. Arakawa, T.; Chong, D.K.; Langridge, W.H. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. *Nat. Biotechnol.* **1998**, *16*, 292–297.
91. Muthamilselvan, T.; Lee, C.W.; Cho, Y.H.; Wu, F.C.; Hu, C.C.; Liang, Y.C.; Lin, N.S.; Hsu, Y.H. A transgenic plant cell-suspension system for expression of epitopes on chimeric bamboo mosaic virus particles. *Plant Biotechnol. J.* **2015**, doi:10.1111/pbi.12377.
92. Plchova, H.; Moravec, T.; Hoffmeisterova, H.; Folwarczna, J.; Cerovska, N. Expression of human papillomavirus 16 E7ggg oncoprotein on N- and C-terminus of potato virus X coat protein in bacterial and plant cells. *Protein Expr. Purif.* **2011**, *77*, 146–152.
93. Kadri, A.; Wege, C.; Jeske, H. *In vivo* self-assembly of TMV-like particles in yeast and bacteria for nanotechnological applications. *J. Virol. Methods* **2013**, *189*, 328–340.
94. Brumfield, S.; Willits, D.; Tang, L.; Johnson, J.E.; Douglas, T.; Young, M. Heterologous expression of the modified coat protein of cowpea chlorotic mottle bromovirus results in the assembly of protein cages with altered architectures and function. *J. Gen. Virol.* **2004**, *85*, 1049–1053.
95. Saunders, K.; Sainsbury, F.; Lomonosoff, G.P. Efficient generation of cowpea mosaic virus empty virus-like particles by the proteolytic processing of precursors in insect cells and plants. *Virology* **2009**, *393*, 329–337.
96. Kumar, S.; Ochoa, W.; Singh, P.; Hsu, C.; Schneemann, A.; Manchester, M.; Olson, M.; Reddy, V. Tomato bushy stunt virus (TBSV), a versatile platform for polyvalent display of antigenic epitopes and vaccine design. *Virology* **2009**, *388*, 185–190.
97. Mueller, A.; Kadri, A.; Jeske, H.; Wege, C. *In vitro* assembly of tobacco mosaic virus coat protein variants derived from fission yeast expression clones or plants. *J. Virol. Methods* **2010**, *166*, 77–85.
98. Arkhipenko, M.V.; Petrova, E.K.; Nikitin, N.A.; Protopopova, A.D.; Dubrovin, E.V.; Yaminskii, I.V.; Rodionova, N.P.; Karpova, O.V.; Atabekov, J.G. Characteristics of artificial virus-like particles assembled *in vitro* from potato virus X coat protein and foreign viral RNAs. *Acta Nat.* **2011**, *3*, 40–46.
99. Tyulkina, L.G.; Skurat, E.V.; Frolova, O.Y.; Komarova, T.V.; Karger, E.M.; Atabekov, I.G. New viral vector for superproduction of epitopes of vaccine proteins in plants. *Acta Nat.* **2011**, *3*, 73–82.
100. Smith, M.L.; Corbo, T.; Bernales, J.; Lindbo, J.A.; Pogue, G.P.; Palmer, K.E.; McCormick, A.A. Assembly of trans-encapsidated recombinant viral vectors engineered from tobacco mosaic virus and semliki forest virus and their evaluation as immunogens. *Virology* **2007**, *358*, 321–333.

101. Atabekov, J.; Nikitin, N.; Arkhipenko, M.; Chirkov, S.; Karpova, O. Thermal transition of native tobacco mosaic virus and rna-free viral proteins into spherical nanoparticles. *J. Gen. Virol.* **2011**, *92*, 453–456.
102. Karpova, O.; Nikitin, N.; Chirkov, S.; Trifonova, E.; Sheveleva, A.; Lazareva, E.; Atabekov, J. Immunogenic compositions assembled from tobacco mosaic virus-generated spherical particle platforms and foreign antigens. *J. Gen. Virol.* **2012**, *93*, 400–407.
103. Phelps, J.P.; Dang, N.; Rasochova, L. Inactivation and purification of cowpea mosaic virus-like particles displaying peptide antigens from *Bacillus anthracis*. *J. Virol. Methods* **2007**, *141*, 146–153.
104. Rae, C.S.; Khor, I.W.; Wang, Q.; Destito, G.; Gonzalez, M.J.; Singh, P.; Thomas, D.M.; Estrada, M.N.; Powell, E.; Finn, M.G.; *et al.* Systemic trafficking of plant virus nanoparticles in mice via the oral route. *Virology* **2005**, *343*, 224–235.
105. Vitti, A.; Piazzolla, G.; Condelli, V.; Nuzzaci, M.; Lanorte, M.T.; Boscia, D.; de Stradis, A.; Antonaci, S.; Piazzolla, P.; Tortorella, C. Cucumber mosaic virus as the expression system for a potential vaccine against Alzheimer's disease. *J. Virol. Methods* **2010**, *169*, 332–340.
106. Rioux, G.; Majeau, N.; Leclerc, D. Mapping the surface-exposed regions of papaya mosaic virus nanoparticles. *FEBS J.* **2012**, *279*, 2004–2011.
107. Wu, L.; Jiang, L.; Zhou, Z.; Fan, J.; Zhang, Q.; Zhu, H.; Han, Q.; Xu, Z. Expression of foot-and-mouth disease virus epitopes in tobacco by a tobacco mosaic virus-based vector. *Vaccine* **2003**, *21*, 4390–4398.
108. Petukhova, N.V.; Gasanova, T.V.; Stepanova, L.A.; Rusova, O.A.; Potapchuk, M.V.; Korotkov, A.V.; Skurat, E.V.; Tsybalova, L.M.; Kiselev, O.I.; Ivanov, P.A.; *et al.* Immunogenicity and protective efficacy of candidate universal influenza a nanovaccines produced in plants by tobacco mosaic virus-based vectors. *Curr. Pharm. Des.* **2013**, *19*, 5587–5600.
109. Bendahmane, M.; Koo, M.; Karrer, E.; Beachy, R.N. Display of epitopes on the surface of tobacco mosaic virus: Impact of charge and isoelectric point of the epitope on virus-host interactions. *J. Mol. Biol.* **1999**, *290*, 9–20.
110. Yin, Z.; Nguyen, H.G.; Chowdhury, S.; Bentley, P.; Bruckman, M.A.; Miermont, A.; Gildersleeve, J.C.; Wang, Q.; Huang, X. Tobacco mosaic virus as a new carrier for tumor associated carbohydrate antigens. *Bioconjug. Chem.* **2012**, *23*, 1694–1703.
111. Rioux, G.; Babin, C.; Majeau, N.; Leclerc, D. Engineering of papaya mosaic virus (PapMV) nanoparticles through fusion of the HA11 peptide to several putative surface-exposed sites. *PLoS ONE* **2012**, *7*, e31925.
112. Porta, C.; Spall, V.E.; Findlay, K.C.; Gergerich, R.C.; Farrance, C.E.; Lomonossoff, G.P. Cowpea mosaic virus-based chimaeras. Effects of inserted peptides on the phenotype, host range, and transmissibility of the modified viruses. *Virology* **2003**, *310*, 50–63.
113. Uhde-Holzem, K.; Fischer, R.; Commandeur, U. Genetic stability of recombinant potato virus X virus vectors presenting foreign epitopes. *Arch. Virol.* **2007**, *152*, 805–811.
114. Werner, S.; Marillonnet, S.; Hause, G.; Klimyuk, V.; Gleba, Y. Immunoabsorbent nanoparticles based on a tobamovirus displaying protein a. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 17678–17683.
115. Plotkin, S.A. Vaccines: Correlates of vaccine-induced immunity. *Clin. Infect. Dis.* **2008**, *47*, 401–409.
116. Khor, I.W.; Lin, T.; Langedijk, J.P.; Johnson, J.E.; Manchester, M. Novel strategy for inhibiting viral entry by use of a cellular receptor-plant virus chimera. *J. Virol.* **2002**, *76*, 4412–4419.

117. Brennan, F.R.; Jones, T.D.; Gilleland, L.B.; Bellaby, T.; Xu, F.; North, P.C.; Thompson, A.; Staczek, J.; Lin, T.; Johnson, J.E.; *et al.* *Pseudomonas aeruginosa* outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus. *Microbiology* **1999**, *145*, 211–220.
118. Storni, T.; Lechner, F.; Erdmann, I.; Bachi, T.; Jegerlehner, A.; Dumrese, T.; Kundig, T.M.; Ruedl, C.; Bachmann, M.F. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. *J. Immunol.* **2002**, *168*, 2880–2886.
119. Safety and Reactogenicity of a PAL Combined with Seasonal Flu Vaccine in Healthy Adults. Available online: <https://clinicaltrials.gov/ct2/show/NCT02188810> (accessed on 11 July 2015).
120. Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults. Available online: <https://clinicaltrials.gov/ct2/show/NCT02013687?term=Pfs25&rank=4> (accessed on 11 July 2015).

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>).